Oncovirus
Recombinant Sendai virus selects for and lyses human tumor cells
Published in Gene Therapy Weekly, September 9th, 2004
According to recent research published in the journal Gene Therapy, "malignant tumor cells often express matrix metalloproteinases (MMPs) at a high level to enable their dissemination and metastasis. Sendai virus (SeV), a nonsegmented negative strand RNA virus, spreads in the target tissues in vivo via cleavage activation of the viral fusion glycoprotein by a tissue-specific, trypsin-like enzyme."
"By deleting the viral matrix protein, we previously generated a recombinant SeV that does not bud to mature virions, but is highly fusogenic and spreads extensively from cell to cell...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2004-09-09)
More Articles from Gene Therapy Weekly
- Fetal Medicine
In utero gene delivery may be capable of treating muscular dystrophy - Pulmonary Medicine
Secretory leukoprotease inhibitor can be targeted for treating lung cancer - Type 1 Diabetes
Vascular endothelial growth factor gene delivery promotes islet vessel growth - Urology
Histone deacetylase inhibitors improve the transfection of bladder cancer cells - Addiction Medicine
Researchers find new hope for detecting gene doping - Anticancer Therapy
Gene-deleted oncolytic adenovirus vector activates cancer therapy - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
